Andere Sprachen Novo Nordisk A/S

Aktien

A3EU6F

DK0062498333

NOVO B

Markt geschlossen - Nasdaq Copenhagen Andere Börsenplätze 16:59:56 26.04.2024			% 5 Tage	% 1. Jan.
886,6 ^DKK	+2,28 %		+2,36 %	+27,00 %

26.04.	WOCHENVORSCHAU: Termine bis 10. Mai 2024	DP
26.04.	WOCHENVORSCHAU/29. April bis 5. Mai (18. KW)	DJ

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Agenda : Apple, Amazon, Eli Lilly et Stellantis arrivent !	26.04.
Nonalcoholic Steatohepatitis Market to Observe Impressive Growth During the Forecast Period \| Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals	26.04.
Scholz promises support for pharma sector in Germany as Merck invests	25.04.
Sector Update: Health Care Stocks Slipping Late Afternoon	24.04.
Sector Update: Health Care	24.04.
Comisión del Senado de EEUU investiga precios de medicamentos para adelgazar Ozempic y Wegovy	24.04.
Novo Nordisk's Wegovy FDA Approval for Heart Health Opens Door to Medicare Access, KKF Says	24.04.
US Senate committee investigates pricing of Novo's Ozempic and Wegovy	24.04.
Novo Nordisk Probed by Senate Committee on Weight-Loss Drug Prices	24.04.
Novo Nordisk A/S : Reduction of the share capital	24.04.
Novo Nordisk A/S - Articles of Association, April 2024	24.04.
Novo Nordisk A/S – Reduction of the share capital	24.04.
Germany's Evotec appoints Christian Wojczewski as CEO	23.04.
UK stocks may finally be back in fashion	23.04.
Health Care Climbs on Earnings Hopes -- Health Care Roundup	22.04.
Eli Lilly to acquire manufacturing facility from Nexus Pharma	22.04.
Novo Nordisk A/S - share repurchase programme	22.04.
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut	21.04.
India's Biocon developing its own version of Wegovy, clinical trial likely next year	18.04.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	15.04.